Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2017
ABPI update on application for judicial review
4 October 2017 - The ABPI have issued a statement regarding its application for judicial review versus NICE. ...
Posted by Michael Wonder on 29 Sep 2017
Price deal sees NICE back Imbruvica for one indication but not another
28 September 2017 - The UK’s NICE has recommended Imbruvica (ibrutinib), within its marketing authorisation, for use on the Cancer ...
Posted by Michael Wonder on 28 Sep 2017
NICE knocks-back Janssen's Imbruvica in Mantle cell lymphoma
28 September 2017 - Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib). ...
Posted by Michael Wonder on 25 Sep 2017
NICE nod for new Eylea indication
22 September 2017 - NICE has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for ...
Posted by Michael Wonder on 20 Sep 2017
Nivolumab now available for lung cancer after company offers NICE new CDF deal
20 September 2017 - Around 1,300 lung cancer patients will receive nivolumab as part of a CDF deal put forward ...
Posted by Michael Wonder on 06 Sep 2017
NICE publishes updated guidance on the use of Nexavar on the NHS
6 September 2017 - NICE has updated its 2010 guidance on the use of sorafenib tosylate (Nexavar) on the NHS ...
Posted by Michael Wonder on 05 Sep 2017
NICE publishes second draft guidance for ixazomib citrate
5 September 2017 - The Department of Health has asked NICE to produce guidance on use of ixazomib citrate (Ninlaro) in ...
Posted by Michael Wonder on 04 Sep 2017
Merck’s Erbitux backed by NICE for head and neck cancer
4 September 2017 - Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell ...
Posted by Michael Wonder on 31 Aug 2017
Final NHS green light for Allergan’s IBS-D drug
31 August 2017 - Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea to be reviewed ...
Posted by Michael Wonder on 28 Aug 2017
NICE terminates appraisal of another cancer medicine
23 August 2017 - NICE has terminated its appraisal of idelalisib with ofatumumab acetate for the treatment of patients with ...
Posted by Michael Wonder on 28 Aug 2017
Europe’s first stem cell therapy backed by NICE
25 August 2017 - Chiesi's Holoclar, the first stem-cell therapy to be cleared by European regulators, has received a green ...
Posted by Michael Wonder on 27 Aug 2017
NICE reverses stance on Takeda’s Adcetris
25 August 2017 - NICE reverses stance on Takeda’s Adcetris. ...
Posted by Michael Wonder on 21 Aug 2017
Pfizer objects to NICE methods in leukaemia drug rejection
21 August 2017 - NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give ...
Posted by Michael Wonder on 14 Aug 2017
NICE turns down kidney cancer drugs
14 August 2017 - It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will ...
Posted by Michael Wonder on 09 Aug 2017
NICE supports the use of another treatment option for patients with renal cell carcinoma on the NHS
9 August 2017 - NICE has completed its appraisal of cabozantinib maleate for patients with previously treated advanced renal cell ...